FDA Grants Onc Drug Accelerated Approval for Key Genetic Driver of Cancer
November 27, 2018
The FDA has granted an accelerated approval to larotrectinib (Vitrakvi, Loxo Oncology) for the treatment of adult and pediatric patients with solid tumors that have an NTRKgene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.